FDA Approves GALLIUM GA-68 PSMA-11 — Ionetix Corporation
Ionetix Corporation announced the FDA approval of Gallium Ga-68 Gozetotide, a generic version of the prostate cancer imaging agent PSMA-11, which is expected to intensify price competition and expand market accessibility for nuclear medicine providers.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day